Skip to end of metadata
Go to start of metadata

 

The American Society of Clinical Oncology (ASCO) has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners and patients with an opportunity to provide feedback or submit evidence on individual published guidelines. All information is open for viewing. However, to comment or submit new evidence, an ASCO Guidelines Wiki user account is needed. To receive your user account, please contact guidelines@asco.org

 

Clinical Practice Guidelines   


 

 Head & Neck Cancer

 

 ASCO Guidelines are reviewed by the Clinical Practice Guidelines Committee and submitted for publication in Journal of  Clinical Oncology (JCO). To view the original guideline publications, please visit the JCO website.  

 

 

 

Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care.Guidelines can address specific clinical situations (disease-oriented) or use of approved medical products, procedures, or tests (modality-oriented). Using the best available evidence, ASCO expert panels identify and develop practice recommendations for specific areas of cancer care that would benefit from using practice guidelines. The criteria for selecting topics for guidelines includes significance of clinical importance; presence of variations in patterns of, or access to care; availability of suitable data; and ethical considerations.

ASCO also publishes Guideline Endorsements and Provisional Clinical Opinions (PCOs). Endorsement of guidelines will be considered in selected circumstances either upon request from peer professional organizations, or when ASCO seeks to endorse another organization’s guideline in lieu of undertaking its own guideline on the same topic. The PCO is intended to offer timely clinical direction to the ASCO membership following the publication or presentation of potentially practice-changing data from major studies. It may serve in some cases as interim direction to the membership pending the development or updating of an ASCO clinical practice guideline.

 

You must have an account to comment or submit evidence. Contact the Guidelines Site Administrator for assistance.

 

 

 

 

ASCO Guideline Disclaimer: The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) to assist practitioners in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action.  The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating physician in the context of treating the individual patient. Use of the information is voluntary.  ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.


The content on the site is for personal use only. Requests for reuse should be directed to permissions@asco.orgTerms & Conditions apply for this site.

 ©2014 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide

 

 

 

Guidelines in Development


  • Second—Line  Hormonal Therapy for Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Consensus-Based Clinical Practice Guideline
  • Management of Small Renal Masses
  • Androgen Deprivation Therapy of Non-Castration Resistant Prostate Cancer
  • Use of Tumor Biomarkers to Guide Treatment Decisions for Patients with Early Stage or Locally Advanced Breast Cancer
  • Use of Tumor Biomarkers to Guide Treatment Decisions for Patients with Advanced Breast Cancer
  • Endocrine Therapy for Hormone-Receptor Positive Advanced Breast Cancer
  • Cardiac Dysfunction in Cancer Survivors
  • Chronic Pain in Cancer Survivors
  • Locally Advanced Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Resectable Pancreatic Cancer
  • Resource Stratified Guidelines for Cervical Cancer Primary Prevention
  • Resource Stratified Guidelines for Cervical Cancer Secondary Prevention/early Disease
  • Resource Stratified Guidelines for Cervical Cancer Diagnosis/Treatment/Palliation
  • Role of Postoperative Radiation Therapy for Endometrial Cancer Endorsement
  • Joint ASCP-CAP-AMP-ASCO Guideline on Molecular Markers for the Evaluation of Colorectal Cancer
  • Joint ASCP-CAP- ASCO HER2 Testing in Gastric Cancer
  • ASCO-SGO Guideline for Neoadjuvant Chemotherapy in Women Diagnosed with Advanced Stage Ovarian Cancer
  • Guideline endorsement of a Guideline for the Prevention of Oral and Oro-pharyngeal Mucositis in Children Receiving Treatment for Cancer or Undergoing Hematopoietic Stem Cell Transplantation
  • Physician-Patient Communication
  • Treatment of SCLC Endorsement
  • Muscle-invasive and Metastatic Bladder Cancer Guideline Endorsement
  • Low-dose brachytherapy in low- or intermediate risk prostate cancer
  • Optimal Adjuvant Chemotherapy Regimens and Adjuvant Targeted Therapy for Early Female Breast Cancer:  American Society of Clinical Oncology Adaptation of a Cancer Care Ontario Guideline
  • Active Surveillance for the Management of Localized Prostate Cancer CCO Endorsement

These guidelines are currently not available for comment. Once they have been published in JCO, ASCO Guideline Wiki users will have the opportunity to comment.

 Updates in Development


 

Recently Updated

 

 

 

 

 

 

 

 

 


  • No labels